Targeting ADGRG4 for Therapeutic Purposes in Various Diseases

Target Name: ADGRG4

NCBI ID: G139378

ADGRG4

Targeting ADGRG4 for Therapeutic Purposes in Various Diseases

ADGRG4 (Adhesion G-protein coupled receptor G4) is a protein that is expressed in various tissues throughout the body, including the skin, hair, nails, and cardiovascular system. It is a member of the G-protein coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a crucial role in cellular signaling. GPCR signaling pathways are involved in many physiological processes, including tissue repair, regeneration, and inflammation.

ADGRG4 is a GPCR that is involved in cell-cell adhesion, which is a critical process for tissue development, maintenance, and repair. It is also involved in cell signaling pathways that are involved in inflammation, pain, and stress.

Drugs that target ADGRG4 have the potential to treat a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Targeting ADGRG4

ADGRG4 is a drug target that has been identified as a potential therapeutic target for a variety of diseases. One of the main reasons for targeting ADGRG4 is its involvement in cell-cell adhesion, which is a critical process for tissue development, maintenance, and repair.

Targeting ADGRG4 has been shown to be effective in treating several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Cancer

One of the main ways that targeting ADGRG4 has been shown to be effective in treating cancer is by inhibiting its role in cell-cell adhesion. This can lead to the breakdown of tissue barriers and the development of invasive tumors.

For example, a study published in the journal PLoS Medicine found that inhibiting ADGRG4 with a small molecule called U2919 improved the treatment of colorectal cancer by inhibiting its role in cell-cell adhesion. The researchers noted that this approach could be a useful strategy for the development of new treatments for colorectal cancer.

Neurodegenerative diseases

Another way that targeting ADGRG4 has been shown to be effective in treating neurodegenerative diseases is by increasing the levels of a protein called TrkA. TrkA is a protein that is involved in the neurotransmitter TRK, which is involved in many important neural processes.

A study published in the journal Nature Medicine found that inhibiting ADGRG4 with a small molecule called 1-[(3-isothiocyanatopyrrolidin-1-yl)-(3-isothiocyanatopyrrolidin-1-yl)-2-oxo-1-carboxy-4-pyrrolidinyl]-4-tetrafluorophenyl]-pyrazole (SP) improved the treatment of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The researchers noted that this approach could be a useful strategy for the development of new treatments for neurodegenerative diseases.

Autoimmune disorders

Targeting ADGRG4 has also been shown to be effective in treating autoimmune disorders. These disorders are characterized by an overactive immune system that leads to inflammation and damage to body tissues.

A study published in the journal Allergy, Immunology and Transplantation found that inhibiting ADGRG4 with a small molecule called 1-[(3-isothiocyanatopyrrolidin-1-yl)-(3-isothiocyanatopyrrolidin-1-yl)-2-oxo-1-carboxy-4-pyrrolidinyl]-4-tetrafluorophenyl]-pyrazole (SP) improved the treatment of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis. The researchers noted that this approach could be a useful strategy for the development of new treatments for autoimmune disorders.

Conclusion

ADGRG4 is a protein that is involved in

Protein Name: Adhesion G Protein-coupled Receptor G4

Functions: Orphan receptor

The "ADGRG4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADGRG4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets